Glonghui, May 22 | German pharmaceutical company BioNTech (BNTX.US) continued to rise, rising 6.36% to $97.9. On the face of the message. BioNTech will present important clinical trial updates at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the progress of its diverse immuno-oncology product lines, including innovative treatments for various cancers. The company's ambitious goal is to launch the first cancer immunotherapy by 2026 and get approval for 10 cancer indications by 2030, which is a promising development for patients and investors.
美股异动｜BioNTech涨超6% 将于ASCO年会展示重要临床试验更新
Changes in US stocks | BioNTech rose more than 6% to present important clinical trial updates at ASCO's annual meeting
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.